Bupa briefing update: Professor Anand Saggar joins panel

Professor Anand Saggar

We are delighted to announce that Professor Anand Saggar will join the panel for our Bupa briefing on Thursday, 17 July.

A senior consultant in clinical genetics, Professor Saggar is ex-President of the Medical Genetics section at the Royal Society of Medicine and former Secretary of the Clinical Genetics Society. He works privately and out of the Royal Brompton and Harefield NHS Foundation Trust.

Professor Saggar will join a panel that includes:

• Rebecca Rohrer, Bupa’s Clinical Innovation and Genomics Director
• Daniel Sullivan, Director of Proposition & Customer for Genomics
• Jody Drew, Bupa employee whose medication check revealed how her body would respond to drugs that linked to her own family history of cancer

Unlocking the Future of Personalised Healthcare

Date: Thursday 17 July
Time: 11.15 am
Location: Online – exclusive to MJA members

This exclusive online briefing offers MJA members the opportunity to catch an early insight into an ambitious genomic healthcare project being led by Bupa.

This behind-the-headlines event comes as Bupa prepares to launch a series of consumer-facing DNA products designed to transform personalised and preventative healthcare. It follows the company’s 2024 pilot of whole genome sequencing in over 3,700 patients — a move that revealed significant insights into cancer risk, medication sensitivity, and genetic predispositions to chronic illness.

The following new products will be discussed:

1. Medication Check (launching July): A DNA-based test helping people understand which medicines are more likely to work for them, and which might not work or cause increased side effects. This test will help people to get the right medicine, at the right dose at the first time. Pilot data revealed 99% of participants had at least one gene variant impacting how they process common medicines.
2. DNA Health Check: Now in trial, this test aims to give patients early warning of increased genetic risks for major conditions including breast and prostate cancer, Type 2 diabetes and cardiovascular disease — enabling them to act sooner.
3. Advanced DNA Check (launching October): The most comprehensive test in the portfolio, combining insights from medication, disease risk, carrier status, and traits to give a fuller picture of an individual’s health profile — with guidance on action and support.

Don’t miss this exclusive chance for health, science and consumer journalists to get ahead of the news and learn about the project and how wider healthcare, including the NHS, could follow suit.

The session will include a short presentation, followed by an in-depth Q&A designed to give journalists access to exclusive data, early insight into rollout plans, and the opportunity to probe Bupa’s strategy for consumer genomics at scale.

Places are limited. Register now to secure your spot and gain early insight into one of the most ambitious personalised medicine strategies currently unfolding in the UK.

To join the briefing REGISTER USING THE FORM BELOW

Note: If you have already registered for the event on the original date you do not need to register again. You will automatically be sent an access link for the new date.